A new study describes how injuries deplete the tracheobronchial tissue-specific stem cells pool, leading to compromised epithelial regeneration
You are here
Summaries of the most recent articles published in STEM CELLS and STEM CELLS Translational Medicine.
A review summarizes current findings regarding the functional/developmental heterogeneity of megakaryocytes and potential links to platelet heterogeneity
A new review describes those studies employing neural stem cell-based therapies as a treatment approach for perinatal brain injuries
A new study describes the application of an ex vivo drug delivery device containing immobilized of MSCs to the treatment of acute kidney injury
A new study using an equine model provides further support to the value of mesenchymal stem cell secretome-based treatments for infected wounds
A new review summarizes current research concerning intranasally-administered MSC-EVs administrated and their potential as a therapeutic approach
ELF3 induces the differentiation of mesenchymal stem cells into carcinoma-associated fibroblasts exhibiting an inflammatory phenotype
Researchers describe how to counteract the decline in neurogenesis observed in the V-SVZ in animal models of Parkinson's disease
While megakaryocytes and platelets display more diverse functions than previously appreciated, the molecular and cellular features underlying this diversity remain largely unclear. A new STEM CELLS Translational Medicine from researchers led by Jiaxi Zhou (Chinese Academy of Medical Sciences/Peking Union Medical College, Tianjin, China) summarizes current findings regarding the functional and developmental heterogeneity of megakaryocytes and potential links to platelet heterogeneity, providing new insights into the ex vivo generation of platelets from human pluripotent stem cells and the clinical management of related diseases.
The limited treatment options for perinatal brain injury and the associated life-long burden provide the impetus driving the development of novel neuroregenerative therapies. Now, a new STEM CELLS Translational Medicine article from researchers led by Megan Finch-Edmondson (University of Sydney, Sydney, New South Wales) and Courtney A. McDonald (Hudson Institute of Medical Research, Clayton, Victoria, Australia) critically review those studies employing neural stem cell (NSC)-based therapies for perinatal brain injuries. Smith et al. also discuss the critical future research required for the clinical translation of NSC therapy for perinatal brain injury, including large animal studies, investigations into the need for neonatal immunosuppression, and the standardization of clinically-relevant behavioral outcomes.
The conventional intravascular administration of mesenchymal stem cells (MSCs) leads to the low persistence of cells and a shortened therapeutic window. Now, researchers led by Biju Parekkadan (Rutgers University, Piscataway, NJ, USA) describe the immobilization of MSCs within an ex vivo drug delivery device that circulates the patient's blood akin to a dialysis procedure. In their recent STEM CELLS Translational Medicine study, Swaminathan et al. report the first use of this technology in human patients with acute kidney injury (AKI). Overall, the data from this phase I/II trial support the therapeutic hypothesis that ex vivo delivery of MSC-secreted factors leads to immunomodulation, reprogramming of immune cells, and subsequent protection of kidney injury.
A new STEM CELLS Translational Medicine article from researchers led by Gerlinde R. Van de Walle (Cornell University, Ithaca, NY, USA) demonstrates that the equine mesenchymal stem cell (MSC) secretome effectively reduces the viability of methicillin-resistant Staphylococcus aureus (MRSA) biofilms in an ex vivo cutaneous wound explant model. Moreover, Marx et al. also report that the MSC secretome actively modulated immune responses of keratinocytes via a CCL2-mediated mechanism. Collectively, this article provides further support for the value of MSC secretome-based treatments for infected wounds.
Treating neurological disorders remains a challenge due to the implication of multifactorial, complex etiologies. In recent years, the therapeutic benefits of the intranasal administration of extracellular vesicles isolated from mesenchymal stem cells (MSC-EVs) have gained attention. Extracellular vesicles retain the advantages of their parental cells, while intranasal administration provides a non-invasive method to bypass the blood-brain barrier and target specific pathological regions. In a recent STEM CELLS review article, researchers led by Daniel Offen (Tel Aviv University, Israel) summarize the current status of research into MSC-EVs administrated via the intranasal pathways and the potential of this promising therapeutic approach.
The mechanisms determining the heterogeneity of stromal populations in the tumor microenvironment remain poorly understood. A recent STEM CELLS study from the lab of David R. Rowley (Baylor College of Medicine, Houston, TX, USA) identifies ELF3 (E74 Like ETS Transcription Factor 3) as an essential transcription factor regulating the differentiation of a critical pro-inflammatory stromal cell type (carcinoma-associated fibroblasts exhibiting an inflammatory phenotype or iCAFs) and provides evidence for mesenchymal stem cells (MSCs) as iCAF progenitors cells.
Parkinson's disease is a major neurodegenerative disease and how the lack of dopamine affects neurogenesis in the ventricular-subventricular zone (V-SVZ) remains unclear. In a new STEM CELLS article, researchers led by José Luis Labandeira-Garcia and Jannette Rodríguez-Pallares (Universidade de Santiago de Compostela, Spain) show that dopamine increases proliferation and generation of neuroblasts in the V-SVZ and that the blockade of angiotensin AT2 receptors suppresses these effects, showing a functional dependence between dopamine and the renin-angiotensin system (RAS). More importantly, Garcia-Garrote et al. establish that the blockade of angiotensin AT1 receptors or stimulation of angiotensin AT2 receptors can counteract the decline in neurogenesis observed in the V-SVZ in animal models of Parkinson's disease.
A new STEM CELLS Translational Medicine article from researchers led by Chunmeng Shi and Yu Wang (Army Medical University, Chongqing, China) reports on the activation and reprogramming of fibroblasts into a neural cell-like state following wounding and how their direct contact with local nerves promotes axon regrowth through the ID1/ID3-Itga6 pathway. Chen et al. also established that the transplantation of ID1/ID3 fibroblasts significantly improved local nerve regeneration following wounding. The results of the present study increase our current understanding of the pathophysiology of local nerve injury and may aid the challenge of treating peripheral nerve disorders and peripheral neuropathies in relatively chronic refractory wounds.
Human mesenchymal stem cell (MSC) therapy represents a potentially exciting treatment choice for disorders resulting from an inflammatory/heightened immune response. In a new STEM CELLS Translational Medicine study from the labs of Carl A. Gregory and Roland Kaunas (Texas A&M Health Science Center, Bryan, TX, USA), researchers report on their studies regarding the therapeutic development of induced pluripotent stem cell-derived MSCs (iPSC-MSCs) Rogers et al. established procedures for the manufacture of iPSC-MSCs attached to novel digestible microcarriers in scalable bioreactors that permitted rapid harvest at high yields and viability. Overall, this study represents the first description of a robust, scalable, and cost-effective method for generating human iPSC-MSCs, which represents a significant contribution to their translational potential. Image - Osteogenic and adipogenic differentiation potential after RWVB expansion on GelMA microcarriers.
A recent STEM CELLS Translational Medicine article from researchers led by Pawan Kumar Gupta (Stempeutics Research Pvt. Ltd, Bangalore, India) reports on their continued study of the safety and efficacy of Stempeucel®, an ex-vivo cultured, pooled, human bone marrow-derived adult allogeneic mesenchymal stromal cell product, in critical limb ischemia associated with Buerger's disease. The authors report continued long-term efficacy over a period of twelve months follow-up, corroborating the result obtained in earlier phase II studies, with significant improvements observed in rest pain, systolic ankle pressure, and ankle-brachial pressure index with accelerated ulcer healing. Overall, the safe and tolerable intramuscular administration of Stempeucel® may represent an effective alternative treatment in patients with Buerger's disease.